TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02617 TRANSTHERA-B

Pre-opening 12-12 09:04:15

157.800

+0.000

0.00%

High157.800	Low157.800	Vol0.00
Open157.800	D1 Closing157.800	Amplitude0.00%
Mkt Cap62.65B	Tradable Cap47.60B	Total Shares397.00M
T/O0.00	T/O Rate0.00%	Tradable Shares301.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":157.8,"timestamp":1765501200005,"preClose":157.8,"halted":0,"volume":0,"delay":0,"floatShares":301666673,"shares":397000000,"eps":-0.7941001070455853,"marketStatus":"Pre-opening","change":0,"latestTime":"12-12 09:04:15","open":157.8,"high":157.8,"low":157.8,"amount":0,"amplitude":0,"askPrice":167,"askSize":1000,"bidPrice":151.6,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.6850652304250384,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765503000000},"marketStatusCode":1,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":157.8,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617/tweets","defaultTab":"tweets","newsList":[{"id":"2589868705","title":"TransThera Sciences Reports Positive Phase 2 Results for Tinengotinib in Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589868705","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589868705?lang=en_us&edition=fundamental","pubTime":"2025-12-05 12:32","pubTimestamp":1764909130,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib  in patients with cholangiocarcinoma . The findings have been published in The Lancet Gastroenterology and Hepatology. The multicenter, open-label Phase 2 trial enrolled patients with FGFR2 fusion-positive CCA who had demonstrated resistance to prior FGFR inhibitor therapy, as well as patients with other FGFR alterations and FGFR wild-type tumors. Tinengotinib demonstrated clinical activity, including durable responses and meaningful clinical benefit, in patients with FGFR2 fusion-positive CCA with acquired resistance to FGFR inhibitors, as well as in other FGFR-altered subtypes. The results support further clinical investigation in a Phase 3 registration study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL9BLJHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2589865231","title":"TransThera Sciences (Nanjing) (SEHK:2617): Assessing a Lofty Valuation After a 200% Three-Month Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865231?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:23","pubTimestamp":1764901415,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in.\nSee our latest analysis for TransThera Sciences (Nanjing).\nThat surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2588008606","title":"BUZZ-TransThera climbs on product inclusion in priority review list","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588008606?lang=en_us&edition=fundamental","pubTime":"2025-12-04 13:38","pubTimestamp":1764826681,"startTime":"0","endTime":"0","summary":"BUZZ-TransThera climbs on product inclusion in priority review list  ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences  Inc 2617.HK climb 3.3% to HK$199.3, on track for the biggest one-day pct rise since November 21** Stock touches the highest level since December 1, on track for the second session of gains** TransThera said its Tinengotinib tablets, for treatment of adults with metastatic cholangiocarcinoma, have been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration  ** Stock, which debuted on June 23, up 1,387% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 78.4%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL1N3XA04Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1153831903","title":"TRANSTHERA-B (02617): Tinengotinib Tablets Approved for Priority Review by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1153831903","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153831903?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:16","pubTimestamp":1764753372,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that Tinengotinib tablets have been approved for inclusion in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2588011148","title":"Tinengotinib Wins Priority Review by China’s National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011148","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011148?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:11","pubTimestamp":1764753090,"startTime":"0","endTime":"0","summary":"Transthera Sciences  Inc. announced that its Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration  of China. The proposed indication is for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma  who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib was also granted Breakthrough Therapy Designation by the NMPA for the treatment of CCA. No other organizations are mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL53n3bG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1103323002","title":"TransThera Sciences (Nanjing), Inc. (02617) Announces Monthly Return on Movements in Securities for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1103323002","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103323002?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:43","pubTimestamp":1764661397,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (02617) published its Monthly Return on Movements in Securities for the period ended 30 November 2025. According to the announcement, the company's authorized...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1118952429","title":"HK Movers | HK's Biotech Shares Soar. Beigene up 4%; TransThera Sciences up 3%; Hengrui Pharma up 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118952429","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118952429?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:46","pubTimestamp":1763430415,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Tuesday.Beigene rose 4%; TransThera Sciences up 3%; Hengrui Pharma rose 2%; Innovent Biologics, Ascletis rose 1%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"502d1227e9e803b590cafd45bb18d9f3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01276","02617"],"gpt_icon":0},{"id":"1163925095","title":"Hong Kong Regains Top Spot in Global IPO Fundraising with Insights from Value Partners Founder Cheah Cheng Hye","url":"https://stock-news.laohu8.com/highlight/detail?id=1163925095","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163925095?lang=en_us&edition=fundamental","pubTime":"2025-11-10 14:12","pubTimestamp":1762755140,"startTime":"0","endTime":"0","summary":"Hong Kong's IPO market has delivered a stellar performance this year, reclaiming its position as the global leader in fundraising, driven by several high-profile listings on the Hong Kong Stock...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00806","LU1807302812.USD","02259","LU1960683339.HKD","IPO","HEXmain","BK1156","BK1610","BK1116","BK1161","BK1198","03750","02617","LU1993786604.SGD"],"gpt_icon":1},{"id":"1186579983","title":"Southbound Capital Flow Data (T+2) | November 10","url":"https://stock-news.laohu8.com/highlight/detail?id=1186579983","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186579983?lang=en_us&edition=fundamental","pubTime":"2025-11-10 07:32","pubTimestamp":1762731166,"startTime":"0","endTime":"0","summary":"On November 5, the top three stocks by net southbound capital inflows were **CSOP Hang Seng Tech ETF (03033)**, **Alibaba-W (09988)**, and **Xiaomi-W (01810)**, with inflows of **HKD 1.286 billion**,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01798","LU1251922891.USD","BK1514","LU2778985437.USD","LU0979878070.USD","LU0181495838.USD","LU0229945570.USD","09988","LU1720050803.USD","SG9999006597.SGD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00B0JY6N72.USD","LU0314109678.HKD","LU2097828474.EUR","HK0000320223.HKD","LU0326950275.SGD","IE00B543WZ88.USD","LU1048596156.SGD","LU0608807946.USD","LU0348816934.USD","LU1769817096.USD","LU0737861772.HKD","LU0048597586.USD","LU1655091459.SGD","LU1880398554.USD","LU1880383366.USD","LU1960683339.HKD","LU0784639295.USD","LU1868837565.USD","LU0130103400.USD","LU1242518857.USD","LU0572940350.SGD","LU0762542818.HKD","LU0235996351.USD","LU0327786744.USD","LU0531970944.HKD","01347","BK1189","LU0791591158.USD","LU2097828557.USD","LU0456854461.SGD","LU0266512473.USD","IE0034224299.USD","LU0650527681.SGD","02015","LU1497733631.SGD","BK1228","SG9999003461.SGD","LU1504937902.USD","BK1588","LU0259732245.USD","LU0762541174.USD","IE00BWDBJ730.SGD","BK1526","BK1200","LU0315178854.USD","IE00BQJZWZ67.USD","00763","IE00BGHQDM52.EUR","LU0607220059.USD","SG9999004220.SGD","LU0516423091.SGD","LU2097828714.EUR","LU0329678337.USD","SG9999000459.SGD","LU1813983027.USD","BK1225","BK1575","LU0261950983.USD","LU0819121731.USD","LU1807302812.USD","LU0477156797.USD","LU1044874839.SGD","LU0228367735.SGD","BK1504","LU0898667661.SGD","LU0823426480.USD","LU0039217434.USD","LU0149534421.HKD","LU0210526637.USD","LU1046422090.SGD","LU0821914370.USD","81024","SG9999001903.USD","LU0823040885.USD","LU1993786604.SGD","LU0823413660.USD","LU0348783233.USD","LU0128522744.USD","LU0043850808.USD","LU0594300419.USD","LU0589944569.HKD","LU0819123356.HKD","BK1180","LU0594300179.USD","02828","SG9999014674.SGD","LU0797268264.HKD","BK1136","LU0169518387.USD","01398","LU0541502299.USD","LU1242518931.SGD","LU0890818403.SGD","LU0543330566.HKD","LU0417516738.SGD","LU0320764243.SGD","LU0127658192.USD","09636","LU0140636845.USD","LU0540923850.HKD","LU0488056044.USD","00257","LU0348784397.USD","LU1235295612.USD","SG9999002828.SGD","00966","LU0873338254.USD","LU0577902454.USD","LU0132412106.USD","00168","LU0048580855.USD","LU0642271901.SGD","LU1810669033.SGD","LU0143863784.USD","LU0128522157.USD","BK1587","IE00BGV7N243.SGD","LU2148510915.USD","IE00BMPRXN33.USD","LU0828237940.HKD","LU0348814723.USD","BK1510","LU0345780521.USD","LU0348767384.USD","IE00BZ08YR35.GBP","LU0577902298.EUR","LU0096374516.USD","LU0561508036.HKD","LU1196710864.SGD","BK1142","LU0630378692.HKD","LU0084288322.USD","HK0000306685.HKD","LU0011963245.USD","LU0211977185.USD","LU1188198961.HKD","LU1282651121.HKD","LU0700851271.USD","LU2488822045.USD","LU0051755006.USD","01055","LU1064130708.USD","LU0651947912.USD","LU0831103253.SGD","LU2125910849.SGD","BK1582","LU0054450605.USD","HBBD.SI","LU0886674414.USD","LU0577902371.SGD","BK1556","LU0708995583.HKD","LU1568876335.HKD","LU2476274720.SGD","LU1328277881.USD","LU1366334578.USD","BK1154","BK1185","BK1149","BK1530","LU1720051108.HKD","LU0541501648.USD","01024","LU0320764755.SGD","BK1505","IE00BVYPNP33.GBP","LU0254981946.USD","LU0572939691.SGD","BK1595","HK0000320264.USD","02899","BK1539","IE00BZ08YS42.EUR","LU0865486749.SGD","BK1560","LU0630378429.USD","LU0052750758.USD","LU2087589342.USD","BK1618","LU0577902611.USD","02617","03143","LU0823041008.USD","LU0061477393.USD","LU0029874905.USD","LU2097829019.USD","LU0441854154.USD","BK1586","BK1528","09626","LU2357305700.SGD","IE00BPRC5H50.USD","BK1604","LU0455707207.USD","LU1282648689.USD","BK1538","LU0531971595.HKD","SG9999006514.SGD","BK1235","02192","BK1592","LU0197773160.USD","LU1481107354.HKD","LU0329678170.USD","BK1231","BK1095","LU0251144936.SGD","LU0348735423.USD","BK1607","HK0000306701.USD","LU1794554557.SGD","LU0608807433.USD","LU1497734951.SGD","LU0348825331.USD","00981","LU0417516571.SGD","LU0611395673.USD","LU0165289439.USD","HK0000165453.HKD","BK1164","LU1211504680.USD","02419","LU2226246903.HKD","LU1201861165.SGD","LU0683595622.HKD","LU0359201885.HKD","LU1769817179.HKD","BK1544","LU2152927971.USD","LU1023057109.AUD","BK1506","SGXZ90724238.SGD","LU0499858602.USD","LU0918141887.USD","LU0130518102.USD","LU0345780281.USD","LU1366334651.USD","00939","LU0049853897.USD","LU0173614495.USD","LU1282649067.USD","SG9999001069.SGD","LU1105468828.SGD","IE00BZ08YT58.USD","02382","LU0164880469.USD","BK1500","LU0469268626.HKD","BK1183","BK1502","BK1529","SG9999000327.SGD","LU0348783662.USD","BK1610","02460","LU0328353924.USD","LU2242644610.SGD","LU1048484197.HKD","LU0359202008.SGD","LU0370786039.SGD","LU2148611432.USD","LU1880383440.USD","SG9999007991.SGD","LU1497733557.USD","00667","XIACY","LU1515016050.SGD","LU1044875133.USD","LU1808992512.USD","LU0856984785.SGD","LU2097828805.USD","SG9999013353.USD","IE00B19Z5X02.USD","LU0449509016.USD","LU0588545904.SGD","LU0499858438.USD","LU1770034418.SGD","IE0003895053.USD","BK1537","LU0593848301.USD","LU0675040207.SGD","LU2449936058.SGD","BK1219","LU0633140727.USD","LU1522347837.USD","KSTmain","IE00B5MMRT66.SGD","BK1608","BK1123","LU3063872942.SGD","BK1584","LU0456846285.SGD","LU0163747925.USD","LU0072462343.USD","LU0516422440.USD","LU0048388663.USD","00308","LU1303224171.USD","LU2125910500.SGD","BK1238","LU0640798160.USD","03866","LU1720051017.SGD","BK1163","BK1614","LU0572944931.SGD","LU1880398471.USD","BK1517","LU0244354667.USD","BK1161","LU0737861699.HKD","LU2293587155.HKD","89988","LU1642822792.SGD","BK1578","LU0210527791.USD","BK1179","LU1048588211.SGD","LU0359201612.USD","LU0823397103.USD","LU0106252389.USD","LU0634319403.HKD","LU0708995153.HKD","LU0672654166.SGD","LU0106259558.USD","BK1125","00883","03969","BK1561","LU0823397285.USD","LU0315179316.USD","LU0143863198.USD","LU0307460666.USD","LU0828237510.HKD","LU2476274308.USD","LU0449515922.USD","SG9999001051.SGD","LU2257852520.SGD","LU0463099449.HKD","BK1550","LU0588546209.SGD","SG9999002463.SGD","LU0543330483.HKD","LU0871576103.HKD","06869","BK1523","LU0396098781.USD","LU1688375341.USD","LU1634259391.SGD","LU1051768304.USD","LU1044876610.USD","LU0164865239.USD","LU0823039010.USD","02039","LU0348788117.USD","LU2213484517.USD","LU1719994722.HKD","LU0117841782.USD","BK1594","BK1198","LU0320764599.SGD","IE0008368304.USD","BK1124","LU1655091616.SGD","IE00B0169N27.USD","03033","LU0266512127.USD","LU0862451753.SGD","80883","BK1558","02800","BK1589","LU0633140560.USD","LU0287142896.SGD","LU0149721374.USD","BK1237","00991","LU0823038988.USD","LU1634259557.SGD","02273","LU0868486357.SGD","LU0502904849.HKD","LU0231483743.USD","BK1590","SG9999002562.SGD","LU0516422952.EUR","00990","LU0228659784.USD","01810","00548","02601","LU0831093199.SGD","BK1615","LU0456827905.SGD","LU0431992006.USD","LU0823426308.USD","BK1249","SG9999001093.SGD","LU0588545730.USD","LU0054237671.USD","BK1104","IE00BMPRXR70.SGD","81810","LU0049112450.USD","LU2045819591.USD","LU0577902538.SGD","LU1831875114.USD","BK1193","BK1140","IE00B29SXG58.USD","LU1548497426.USD","BK1521","MCHmain","BK1552","LU0261947096.USD","LU0214875030.USD","LU0029875118.USD","LU0293314216.USD","LU0648948544.HKD","LU0348766576.USD","LU0918141705.HKD","LU0196878994.USD","BK1591","LU2097828631.EUR","LU1868838027.USD","LU0197773673.USD","LU0264606111.USD","BK1131","LU0345775950.USD","LU0164872284.USD","BK1119","IE00BYV24P56.USD","03403","SG9999001689.USD","LU0348805143.USD","LU0348827113.USD","LU1328615791.USD","LU0047713382.USD","LU1439103000.SGD","LU1316542783.SGD","LU1956131251.USD","LU0516423174.USD","LU1064131003.USD","LU0417516902.SGD","LU1770036033.HKD","LU0651946864.USD","HXXD.SI","LU0823413587.USD","LU1568876251.USD","LU0384037296.USD","LU0117844026.USD","LU0516422366.SGD","LU0791590937.USD","LU1282651048.USD","LU1981816686.USD","LU2399975544.HKD","LU0762540952.USD","LU1224444064.USD","LU0588545490.SGD","BK1507","BK1170","LU1282649810.SGD","LU2039709279.SGD","LU0862451837.USD","LU0345776255.USD","LU1051769294.HKD","LU1115378108.SGD","LU0106959298.USD","BK1501","LU1224709979.USD","LU0605514214.HKD","LU1961090484.USD","BK1184","SG9999001226.SGD","LU0648000940.SGD","LU1282649141.HKD","IE00B3M56506.USD","BK1567","LU1323998911.USD","00639","IE0032431581.USD"],"gpt_icon":1},{"id":"1131237438","title":"TRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine","url":"https://stock-news.laohu8.com/highlight/detail?id=1131237438","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131237438?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:20","pubTimestamp":1762129213,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2580201237","title":"TransThera Sciences and Neurocrine Biosciences Announce NLRP3 Inhibitor Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2580201237","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580201237?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:09","pubTimestamp":1762128575,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced a collaboration with Neurocrine Biosciences, Inc. to develop, manufacture, and commercialize NLRP3 inhibitors for multiple diseases. Under the agreement, Neurocrine will have exclusive rights to the NLRP3 portfolio outside Greater China, while TransThera retains rights within Mainland China, Hong Kong, Taiwan, and Macao. The deal includes an upfront payment to TransThera, with the potential for additional milestone payments, bringing the total value up to US$881.5 million. The partnership also features a research collaboration to further advance NLRP3 technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL8p0G4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2065171311.SGD","LU2324357040.USD","LU0109394709.USD","LU0823416689.USD","LU0320765992.SGD","LU0889565916.HKD","LU2065169927.USD","LU2065171402.SGD","LU0154245673.USD","LU0154245756.USD","BK4139","NBIX","02617","LU2065170008.USD"],"gpt_icon":0},{"id":"2580523745","title":"Transthera Sciences (Nanjing) Inc - Announces Collaboration With Neurocrine Biosciences Inc for Nlrp3 Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2580523745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580523745?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:04","pubTimestamp":1762128279,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WC22J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2580237460","title":"Transthera Sciences (Nanjing) Inc - Agreement Has Potential Value up to $881.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580237460?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:04","pubTimestamp":1762128279,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WC22J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1130889859","title":"HK Movers | HK's Biotech Shares Soar. Xuanzhu Bio up 19%; TransThera up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130889859","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130889859?lang=en_us&edition=fundamental","pubTime":"2025-10-22 10:09","pubTimestamp":1761098996,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.Xuanzhu Bio rose 19%; TransThera rose 13%; Boan Biotech rose 2%; CANbridge rose 1%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"069d3331287d7c7ffedd7cde87c41b57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","02575","02617"],"gpt_icon":0},{"id":"1138043175","title":"Hong Kong Stocks in Motion | TRANSTHERA-B (02617) Rises Over 25% After Presenting Research Data on Tegitnib at 2025 ESMO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1138043175","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138043175?lang=en_us&edition=fundamental","pubTime":"2025-10-22 09:58","pubTimestamp":1761098298,"startTime":"0","endTime":"0","summary":"According to reports, TRANSTHERA-B (02617) saw its shares surge by over 25%, and as of the time of writing, it is up 15.81% at HKD 200, with a trading volume of HKD 712 million. On the news front,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2576856306","title":"TransThera Sciences Plans Hong Kong-Listed Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2576856306","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576856306?lang=en_us&edition=fundamental","pubTime":"2025-10-20 19:33","pubTimestamp":1760960010,"startTime":"0","endTime":"0","summary":"TransThera Sciences'  board approved the conversion of nearly 45 million domestic shares held by 10 shareholders into Hong Kong-listed shares, a Monday Hong Kong bourse filing said.The shares represent roughly 11.33% of the biopharmaceutical company's issued share capital.The Hong Kong-listed share full circulation is subject to the finalization of all details, as well as the relevant regulatory approvals.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1196397575","title":"TransThera (2617) Announces Application for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1196397575","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196397575?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:01","pubTimestamp":1760954473,"startTime":"0","endTime":"0","summary":"On October 20, 2025, TransThera Sciences (Nanjing), Inc. (Stock Code: 2617) disclosed that its board of directors has approved the submission of an application to the China Securities Regulatory...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1100995277","title":"TRANSTHERA-B (02617) Plans to Implement Full H-share Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1100995277","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100995277?lang=en_us&edition=fundamental","pubTime":"2025-10-20 17:54","pubTimestamp":1760954062,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that on October 20, 2025, its board of directors has considered and approved the submission of an application to the China Securities Regulatory Commission (CSRC)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1114971673","title":"From 679 RMB to 112 RMB, then back to 224 RMB: Who is Behind the 'Myth-Making' of TRANSTHERA-B (02617)?","url":"https://stock-news.laohu8.com/highlight/detail?id=1114971673","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114971673?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:44","pubTimestamp":1760701486,"startTime":"0","endTime":"0","summary":"Recently, TRANSTHERA-B (02617) played out another unsettling drama. By analyzing the data, we can clearly observe the complete trajectory behind its K-line chart, which spiraled from violent surges...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1125795824","title":"HK Movers | Biomedical Stocks Jump Again With TransThera Sciences up 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125795824","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125795824?lang=en_us&edition=fundamental","pubTime":"2025-10-17 09:48","pubTimestamp":1760665694,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped again in Hong Kong. TransThera Sciences rose 30%; Duality Biotherapeutics and Biocytogen Pharmaceuticals rose 6%; Alphamab Oncology and CStone Pharmaceuticals rose 5%; Junshi Biosciences rose 4%; Hansoh Pharmaceutical rose 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f3534dded8a211120029b17b865c63fd","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","01877","02616","03692","09966","02315","02617"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.1874},{"period":"1month","weight":-0.2619},{"period":"3month","weight":-0.1803},{"period":"6month","weight":11},{"period":"ytd","weight":11}],"compareEarnings":[{"period":"1week","weight":-0.0156},{"period":"1month","weight":-0.0437},{"period":"3month","weight":-0.0325},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.2667},{"period":"ytd","weight":0.2727}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.","exchange":"SEHK","name":"TRANSTHERA-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRANSTHERA-B,02617,TRANSTHERA-B股票,TRANSTHERA-B股票老虎,TRANSTHERA-B股票老虎国际,TRANSTHERA-B行情,TRANSTHERA-B股票行情,TRANSTHERA-B股价,TRANSTHERA-B股市,TRANSTHERA-B股票价格,TRANSTHERA-B股票交易,TRANSTHERA-B股票购买,TRANSTHERA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}